A recent study by researchers at the University of New South Wales (UNSW) in Australia indicates that adding triethylenetetramine (TETA), commercially known as Cuprior, to the treatment regimen of children with high-risk neuroblastoma may significantly improve their health outcomes. The research highlights the drug's potential to shrink tumors and enhance the immune system's ability to combat the disease.
Mechanism of Action
In tests conducted on mice, Cuprior demonstrated its ability to weaken tumors by facilitating the transfer of copper to immune cells, specifically neutrophils. These white blood cells play a crucial role in fighting infections and diseases. Dr. Orazio Vittorio, the lead researcher from UNSW's School of Biomedical Sciences, explained that the drug exerts a dual effect, weakening the tumor while simultaneously strengthening the immune system, thereby improving the body's response to immunotherapy.
Clinical Implications
Dr. Vittorio suggests that this approach could enhance the effectiveness of current immunotherapy treatments for neuroblastoma, potentially increasing survival rates for affected children from 10 to 50 percent. Neuroblastoma, a cancer that develops from immature nerve cells, primarily affects children aged 5 years or younger. It often originates in the adrenal glands and rarely occurs in older children.
Advantages of Drug Repurposing
Dr. Jordyn Rowan, a principal investigator from UNSW's Clinical Medicine School, described the removal of copper from tumors as a significant breakthrough in treating neuroblastoma. She emphasized that Cuprior is non-toxic and has shown no concerning side effects, potentially improving the quality of life for children suffering from this aggressive cancer. Furthermore, Dr. Rowan noted that repurposing an existing drug like Cuprior saves considerable time and money compared to the 8 to 13 years typically required to develop entirely new treatments.
